Skip to main content
MBRX logo

MBRX · Moleculin Biotech, Inc.

Track MBRX — free
$7.74 -0.19 (-2.40%) At close · Nov 20
Market Cap
$8.22M
Shares
1.06M
Volume · Nov 20 49.56K Avg daily vol (24 sessions) 44.57K

Price & Indicators

 

Key stats

Close
$7.74
Fri 20 Nov
Open
$8.34
Fri 20 Nov
Average volume, 30 days
40K
shares a session
Short interest
55K
5.1% of shares · 1.0 days to cover
Day range
$7.57$8.40
Open $8.34 Close $7.74
52-week closing range
$5.60$213.50
Close $7.74 96.4% under the high
Short volume, last session
65%
Last earnings
May 14, 2025
Latest filing
10-Q · Nov 13
Price history
Jan 2020 to Nov 2026

Up next

call held May 14, 2025

Latest documents

2026
Nov 18
Current report 8-K
South Korea Grants Patent for Method of Reconstituting Liposomal Annamycin

South Korea's Ministry of Intellectual Property has issued a decision to grant a patent covering the method of reconstituting liposomal Annamycin, adding another major market to its patent estate spanning more than 20 jurisdictions.

Regulation FD disclosure
2 source passages
South Korea’s Ministry of Intellectual Property has issued a decision to grant a patent covering the Company’s method of reconstituting liposomal Annamycin more than 20 jurisdictions in North America, Europe, Asia-Pacific and other key regions Open the document at this passage
Nov 16
Current report 8-K
Part A treatment completed for all 90 MIRACLE patients

Moleculin Biotech, Inc. completed Part A treatment for all 90 patients in the Phase 2/3 MIRACLE trial, with comprehensive data on track for the first quarter of 2027. Third-quarter net loss was approximately $6.5 million.

Financial results
2 source passages
Completed treatment for all 90 patients in Part A of the Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML. The Company remains on track for a comprehensive data readout in the first quarter of 2027. Net loss for the third quarter of 2026 was approximately $6.5 million, compared to approximately $25.4 million for the same period in 2025. Open the document at this passage
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
MIRACLE enrollment closes at 90; data expected in 2027

Moleculin closed MIRACLE Part A enrollment at 90 subjects; data are expected in the first quarter of 2027, after interim complete remission rates of 43% and 36% in two Annamycin arms versus 12% for control.

Revenue $0 Net loss $6.49M
Read from the MD&A section
4 source passages
On September 29, 2026, we announced that we have completed and closed enrollment in Part A of our pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML), with 90 subjects enrolled. With Part A enrollment closed, we remain on track for our planned comprehensive data readout of Part A in the first quarter of 2027. Moleculin is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name “naxtarubicin”, which we believe is a “next-generation” anthracycline and, with it, are conducting a pivotal Phase 2/3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). CR reached 43% and 36% in the respective Annamycin cohorts, compared with 12% for control, while CRc reached 50% and 57%, respectively, versus 29% for the control arm; Open the document at this passage
Nov 12
Current report 8-K
Australian Patent Granted for Annamycin Formulation Technology

Moleculin Biotech announced Australian Patent No. 2020303572, covering preparation of preliposomal Annamycin lyophilizate, granted to Moleculin and The Board of Regents of The University of Texas System, strengthening intellectual property protection for its investigational anthracycline Annamycin.

Regulation FD disclosure
3 source passages
issued a press release which announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company’s intellectual property protection for a key aspect of Annamycin’s formulation technology. Australian Patent No. 2020303572 was granted to Moleculin and The Board of Regents of The University of Texas System. The patent titled, “Preparation of Preliposomal Annamycin Lyophilizate,” addresses the preparation of Annamycin’s formulation. Open the document at this passage
Nov 10
Current report 8-K
Annamycin plus PD-1 blockade extended pancreatic cancer survival

Moleculin Biotech said Annamycin (naxtarubicin) combined with PD-1 immune checkpoint blockade significantly increased survival in pancreatic cancer models versus either agent alone, with the result reconfirmed in a second experiment.

Regulation FD disclosure
Source passage
Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced new preclinical data showing that its lead drug candidate, Annamycin (naxtarubicin), combined with PD-1 immune checkpoint blockade, extended survival in pancreatic cancer models beyond that achieved with either agent alone. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$11.42M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$7.29M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+942.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.1%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −78%
below
Price vs 50-day avg −17%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 1%
near low
Momentum
relative strength
Weak
1-month return +19%
trailing
6-month return −85%
trailing
YTD return −88%
this year
Relative strength −76%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $9 › 200d $35 — 200d above 50d
Institutional flow Accumulating
+15% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.14% of shares out · ▲ +763.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
23 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Fair
Free cash flow $-22.7M
Balance sheet $8.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 138%
annualized · 1-yr
Max drawdown −97%
past year
ATR 12.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−78% Bearish
Price vs 50-day avg
−17% Bearish
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $9 › 200d $35 — 200d above 50d
Institutional flow Accumulating
+15% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.14% of shares out · ▲ +763.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
23 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6 Now $8 · 1% Range high $214
vs 200-day avg -78% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Net cash used in operating activities $21.7M Nine months ended September 30, 2026 —
Gross proceeds from shares sold pursuant to the 2025 ATM Agreement $0.8M the three months ended September 30, 2026 filing —
Shares of common stock sold pursuant to the 2025 ATM Agreement 69,969 the three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MBRX
Moleculin Biotech, Inc.
this stock
$8.22M — — — 5.1%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
23
% held
3.0%
Net QoQ
+21.3K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Rising
Shares short
54.5K
Days to cover
1.0d
Change
+48.2K sh
View
Short Volume
Short vol %
65%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
1.2K
Value
$10.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-33.6M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 18, 2026
This year
60

South Korea's Ministry of Intellectual Property has issued a decision to grant a patent covering the method of reconstituting liposomal Annamycin, adding another major market to its patent estate spanning more than 20 jurisdictions.

View
Earnings & Events
Webcasts
Last webcast
Sep 11, 2026
View
Investor Relations
Latest news
Moleculin Strengthens Global Inte…
Published
Nov 18, 2026
View

Performance

5D 20D 120D MTD YTD
MBRX -1.7% +19.1% -85.3% -2.0% -88.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +6.9% +28.3% -76.2% +6.7% -89.5%
Key facts CIK 1659617 CUSIP 60855D507 13F (30d) 32 filings 22 filers Visit website Investor relations